Published: 13 October 2016
Author(s): Cornelius Engelmann, Katrin Splith, Thomas Berg, Moritz Schmelzle
Issue: October 2016
Section: Letter to the Editor

Acute liver failure (ALF) as well as acute-on-chronic liver failure (ACLF) in patients with pre-existing chronic liver disease are defined by rapid deterioration of liver function in association with failure of one or more organs and a poor prognosis. Short-term mortality rates reach 75.5% in ACLF [1] and 80% in ALF [2]. Effective treatment options aimed at improving liver function and limiting inflammation are still lacking. Hence, current therapeutic strategies focus on targeting the triggering event and improving the management of complications such as bleeding, hepatic encephalopathy and bacterial infections, among others [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.